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Abstract The phosphorylation state of PHAS-I is thought to be 
important in the regulation of protein synthesis initiation. 
PHAS-I phosphorylation significantly increases in response to 
growth factors and insulin. ERK1/ERK2 have previously been 
implicated as PHAS-I kinases. Present work utilised a specific 
phosphorothioate oligonucleotide antisense strategy against 
ERK1/ERK2 to determine whether ERK1/ERK2 mediate FBS-
stimulated PHAS-I phosphorylation in vivo. Depleting > 90% of 
cellular ERK1/ERK2 had no effect on FBS-stimulated PHAS-I 
phosphorylation. However, treatment of cells with a specific 
p70S8k pathway inhibitor, rapamycin, markedly attenuated FBS-
stimulated PHAS-I phosphorylation. These results indicate that 
PHAS-I phosphorylation in response to FBS occurs through an 
ERKl/ERK2-independent and rapamycin-sensitive pathway in 
3T3-L1 adipocytes. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Growth factor stimulation of quiescent cells activates a 
complex array of biochemical events resulting in cell growth 
and proliferation [1]. Extracellular signals are propagated to 
their intracellular targets through a network of Ser/Thr kinase 
cascades which exist within the cell. Two such kinase cascades 
result in the independent activation of ERK1/ERK2 and 
p70S6k [2]. These two kinase cascades are thought to be major 
players in the transmission of extracellular information from 
the cell surface to the nucleus. 
One early step in the proliferative response is the activation 
of protein synthesis. Translational regulation is a complicated 
process in which the initiation phase is generally rate-limiting 
(see [3]). Location of the AUG start codon is a major event in 
initiation, mediated by proteins termed eukaryotic initiation 
factors (elF). All eukaryotic cytoplasmic mRNA bears a 'cap' 
structure containing a 7-methylguanosine moiety at the 5' end 
(see [4]). Initiation of translation involves the recognition of 
the capped mRNA, melting of any secondary structure in the 
5' non-translated region and binding of the 40S smaller sub-
unit of the ribosome. This is mediated by a complex desig-
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nated eIF-4F, composed of a cap binding protein (eIF-4E), a 
bi-directional RNA helicase (eIF-4A), and an essential large 
subunit (p220) of unknown function. 
Interest has centred on the involvement of PHAS-I [5] in 
the regulation of protein synthesis initiation. PHAS-I was first 
identified as a heat- and acid-stable protein whose phosphor-
ylation was rapidly enhanced in response to insulin in rat 
adipocytes [6]. It has since been shown that the level of 
PHAS-I phosphorylation increases in response to EGF, 
PDGF, FBS [7] and phorbol esters [8]. In quiescent cells, 
PHAS-I interacts specifically with the translation initiation 
factor eIF-4E, preventing binding of eIF-4E to the mRNA 
5' 'cap' structure [4]. However, PHAS-I phosphorylation in 
response to insulin causes dissociation of PHAS-I from elF-
4E, in rat adipose tissue [4]. Therefore, the phosphorylation 
state of PHAS-I is believed to be one mechanism by which the 
initiation phase of translation is regulated. 
One issue of importance is the elucidation of the kinase 
cascade responsible for PHAS-I phosphorylation. Recently, 
several reports have implicated ERK1/ERK2 in insulin-stimu-
lated PHAS-I phosphorylation [9,10]. Other agonists (includ-
ing FBS) have been shown to cause an increase in the level of 
PHAS-I phosphorylation in 3T3-L1 adipocytes [7,8]. How-
ever, the mechanism controlling PHAS-I phosphorylation in 
response to FBS has not yet been investigated. In order to 
rigorously determine whether the ERK signalling cascade 
plays a role in FBS-stimulated PHAS-I phosphorylation, a 
method of specifically and potently inhibiting ERK activity 
was required. To this end, we have employed an ERK1/ERK2 
specific phosphorothioate antisense strategy which is capable 
of depleting significant levels of ERK protein ( ~ 95%) from 
intact cells [11-13]. For comparison, rapamycin (a specific 
p70S6k pathway inhibitor) was used to test for the involvement 
of the p70S6k pathway in FBS-stimulated PHAS-I phosphor-
ylation. 
Using these tools, direct evidence was obtained suggesting 
that PHAS-I phosphorylation in response to FBS occurred 
through an ERK1/ERK2 independent and rapamycin sensi-
tive pathway, in 3T3-L1 adipocytes. 
2. Materials and methods 
2.1. 3T3-L1 adipocytes 
3T3-L1 fibroblasts were a kind gift from Dr. G. Gould, University 
of Glasgow, UK. Cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM, 1 g/1 glucose, Gibco) and 10% FBS (Sigma) at 
37°C, in the presence of 5% CO2. Medium was changed at 48-h 
intervals. For adipocyte preparation, 3T3-L1 fibroblasts were used 
at passage 6-9 in 22-mm dishes. At 2-3 days post-confluence cells 
were differentiated as described in [14]. Adipocytes were routinely 
used between days 8 and 17 post-differentiation. 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)00266-4 
180 
2.2. Oligonucleotide treatment of cells 
Phosphorothioate modified oligonucleotides were kindly synthe-
sised by Dr. M. Pickett, Department of Microbiology, Southampton 
General Hospital. Oligonucleotide preparation was as described in 
[11]. The phosphorothioate oligonucleotides used in this study were 
as described in [11]. Lipofectin reagent (Gibco-BRL) was used to 
facilitate the introduction of phosphorothioate oligonucleotides into 
cells. 
Lipofectin reagent (100 ug/ml) w a s allowed to pre-incubate with 
DMEM (no additions) for 30-45 min. Stock oligonucleotide was di-
luted in DMEM (no additions) to obtain a solution of 4 times the 
final concentration. An equal volume (routinely 110 ul) of both lip-
ofectin- and DNA-containing solutions were mixed thoroughly and 
left to incubate at room temperature for 15 min. During this time, 
cells were washed (3x1 ml) with pre-warmed DMEM (no additions; 
37°C). Cells were then incubated with an equal volume (200 ul) of 
DMEM (no additions) and the DNA/lipofectin mixture - the trans-
fection medium was of 400 JJ.1 final volume, containing 25 (Xg/ml lip-
ofectin and 10 uM oligonucleotide. Cells were incubated in the pres-
ence of lipofectin for 8 h. The transfection medium was then replaced 
with DMEM (supplemented with 0.25% (w/v) BSA) and the oligonu-
cleotide concentration was maintained. An additional medium change 
was performed after a further 48hrs. Cells were routinely incubated in 
the presence of oligonucleotide for a total of 72 h. 
2.3. 3 2P labelling of and extraction of 3T3-L1 adipocytes 
The protocol was based on that described in [7]. Quiescent cells 
were washed (3x1 ml) in prewarmed buffer A (25 mM HEPES, pH 
7.4. 168 mM NaCl, 4.7 mM KC1, 1.4 mM CaCl2, 1.2 mM MgS04 , 25 
mM NaHCC>3 and 25mM D-glucose). Cells were labelled by adding 
400 ul of incubation buffer (buffer A plus 1% (w/v) BSA and 0.2 mCi 
of carrier-free [32P]Pi per ml), and were incubated in a humid atmos-
phere (5% C02/air; Modular incubator chamber, Flow laboratories). 
Where indicated in figure legends, for the final 30 min, rapamycin (10 
nM final concentration; Calbiochem) or diluent (0.005% DMSO) was 
added. After 2 h in incubation buffer, cells were challenged with FBS 
(20%; see figure legends) and the incubation was continued for 15 
min. Plates were then placed on ice, washed with ice-cold TBS (10 
mM Tris-HCl, pH 7.4; 3X1 ml) and extracted into 120 ul ice-cold 
buffer B (50 mM Tris-HCl, pH 7.4 (4°C), 100 mM NaF, 10 mM 
EDTA, 5 mM DTT, 250 mM sucrose, 1% (w/v) Zwittergent 3-12 
and 50mM benzamidine). Cell extracts were homogenised and then 
centrifuged (3000 Xg, 3 min, room temp) to obtain a post-nuclear 
homogenate. This supernatant was then divided into portions: 10 ul 
was assayed for protein content (Bradford reagent; Biorad); 30 ul was 
prepared for SDS-PAGE by boiling with X 5 Laemmli buffer (3 min, 
100°C). The remainder (~50 ul) was boiled for 10 min to enrich for 
heat stable proteins. Denatured protein was pelleted by centrifugation 
(12000Xg, 20 min, room temp.) and the heat-stable fraction was 
prepared for SDS-PAGE as stated previously. 
2.4. SDS-PAGE 
Cell extracts (typically 15 ug total protein) were subjected to SDS-
PAGE, using a Hoefer gel apparatus (8 cmX 8 cm resolving gel). For 
the preparation of slab gels a low bis-acrylamide stock (30% (w/v) 
acrylamide/0.36% (w/v) A^/V-mefhylene-bis-acrylamide) was used. Re-
solving gels for the separation of heat-stable extract for visualisation 
of PHAS-I were 15% (w/v) acrylamide. Those used for anti-ERK 
Western blots were 12% (w/v) acrylamide. The acrylamide concentra-
tion of the stacking gel was 4% throughout. 
2.5. Western blotting 
ERK gel shift Western blots were routinely used in order to deter-
mine ERK activation. For this, cell extracts were separated by SDS-
PAGE (see Section 2.4). Proteins were then transferred from gels to 
PVDF membranes (0.45 um pore size, Millipore) using a Hoefer semi-
dry transfer apparatus (70 mAmp, 90 min), with 20% methanol, 25 
mM Tris base and 192 mM glycine as the transfer buffer. Membranes 
were blocked overnight in TBS-Tween 20 (20 mM Tris, pH 7.4, 137 
mM NaCl, 0.1% (v/v) Tween 20) containing 5% BSA. Membranes 
were then probed with a monoclonal anti-MAP kinase antibody 
(0.1 ug/ml; Zymed Laboratories Inc., IgG, clone No. Z033) for 2 h 
at room temperature After extensive washing (4X5 min in blocking 
buffer), membranes were incubated in blocking buffer containing a 
1:10000 dilution of goat anti-mouse antibody conjugated to horse-
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radish peroxidase (Sera-lab) for 60 min. Further washing of mem-
branes was then performed (5X5 min; TBS-Tween 20). Immunoreac-
tive bands were visualised using ECL reagent (Amersham 
International) and Hyperfilm-MP (Amersham International). 
2.6. Quantitation of autoradiographs and Western blots by 
densitometry 
In order to determine the intensity of bands on Western blots and 
autoradiographs, they were scanned using an Epson scanner and ap-
propriate software. The image generated was then quantitated using 
'Phoretix' densitometry software. 
3. Results 
3.1. PHAS-I phosphorylation in response to FBS is not 
inhibited by EAS1 treatment of 3T3-L1 adipocytes 
The specific antisense ODN approach used was as described 
in [11]. As judged by Western blotting experiments, ~ 9 5 % 
ERK1/ERK2 depletion was observed in 3T3-L1 adipocytes 
after 72 h treatment with 10 \xM of the antisense ODN, des-
ignated EAS1 (Fig. 1C, lanes 3 and 4), when compared with 
no ODN controls (Fig. 1C, lanes 1 and 2). A scrambled ODN 
was used as an additional control. Cells incubated in the pres-
ence of 10 uM scrambled ODN showed no ERK1/ERK2 
depletion (Fig. 1C, lanes 5 and 6), in contrast to those treated 
with EAS1. Based on a broad range of criteria, it has been 
demonstrated that EAS1 is specific for depletion of ERK1/ 
ERK2 [11-13]. 
The protocol used to visualise PHAS-I was based on that in 
[7]. In quiescent cells, this heat-stable protein migrates as a 
'doublet' on SDS-PAGE with an apparent molecular mass of 
22 kDa (Fig. 1A, lane 1). The upper band of the doublet 
displays a decreased electrophoretic mobility due to its greater 
extent of phosphorylation [10]. Upon FBS stimulation, a de-
crease in the intensity of the lower band occurred in parallel 
with increased 32P incorporation into the upper band (Fig. 
1A, lane 2). This 'band-shift' is characteristic of PHAS-I phos-
phorylation. 
EAS1 treatment had no effect on FBS-stimulated PHAS-I 
band-shift, when compared with no ODN and scrambled 
ODN control cells (Fig. 1A, lane 4 compared with lanes 2 
and 6). Moreover, no significant change in the level of 32P 
incorporated into the upper band of PHAS-I was observed 
in the EAS1 or scrambled ODN conditions in comparison to 
the no ODN controls (Fig. IB). Quantitation of anti-ERK 
Western blots of these same extracts verified ~ 95% depletion 
in levels of ERK2 after cells were treated with EAS1 (Fig. 
1C,D). These results indicate that ERK1/ERK2 do not medi-
ate in FBS-stimulated PHAS-I phosphorylation. 
With this in mind, we considered the p70S6k cascade to be a 
possible candidate for mediating PHAS-I phosphorylation in 
response to FBS. To this end, rapamycin was employed. Ra-
pamycin has been shown to selectively block mitogen induced 
activation of p70S6k and to rapidly inactivate this kinase in 
mitogen-stimulated cells, without affecting the activation of 
p74raf, ERK2, or p90rsk - kinases which are also activated 
within minutes of mitogen stimulation [15-18]. 
3.2. Rapamycin attenuates FBS-stimulated PHAS-I 
phosphorylation in 3T3-L1 adipocytes 
As seen previously, PHAS-I is present as a doublet in con-
trol cells (Fig. 2A, lane 1) and FBS stimulation results in 
increased 32P incorporation into the upper band, with a con-
comitant decrease in the lower band (Fig. 2A, lane 3 and Fig. 
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Fig. 1. EAS1 treatment of 3T3-L1 adipocytes does not inhibit PHAS-I phosphorylation in response to FBS. Cells were treated with or without 
ODN for 72 h as indicated. After 32P labelling, cells were incubated in the presence (+) or absence (-) of FBS (20%) for 10 min. A: Autora-
diograph showing phosphorylation of PHAS-I. B: Quantitation by densitometry of PHAS-I phosphorylation seen in A, where 100% is taken to 
be the total 32P incorporated into the upper band and lower band. C: Western blot (using an anti-ERK antibody) of extracts from the same 
experiment. D: Quantitation of ERK2 expression, where the level of ERK2 in non-stimulated, no ODN cells was taken to be 100%. Results 
are expressed as means ± half the difference. 
2B). However, incubation of cells with rapamycin prior to 
FBS-stimulation, markedly attenuates this band-shift phe-
nomenon - a doublet is seen in which the level of 32P incor-
porated into the upper and lower band is approximately equal 
(Fig. 2A, lane 4 and Fig. 2B). This suggests that pre-treatment 
of 3T3-L1 adipocytes with rapamycin causes significant inhib-
ition of PHAS-I phosphorylation in response to FBS. In ad-
dition, a study of the raw data (see Fig. 2 legend) indicates a 
significant reduction in the total 32P incorporated into PHAS-
I in rapamycin-treated FBS-stimulated cells (Fig. 2A, lane 4), 
when compared with control unstimulated cells (Fig. 2A, lane 
1). 
ERK2 activation can be judged by band-shift on anti-ERK 
Western blots [19-21]. The level of ERK activation measured 
by these blots has previously been shown to correlate well 
with that obtained by MBP kinase assay [22]. Western blot-
ting of the same extracts showed that FBS-stimulation of 3T3-
Ll adipocytes caused robust activation of ERK2 (~65%, as 
measured by densitometry; Fig. 2C, lanes 3 and 4 and Fig. 
2D) in the presence or absence of rapamycin. This suggests 
that the rapamycin-mediated attenuation of PHAS-I phos-
phorylation in response to FBS was independent of ERK2 
activation. 
To summarise, PHAS-I phosphorylation in response to 
FBS appears to be unrelated to the level of cellular ERK 
protein or ERK activation. However, the selective p70S6k 
pathway inhibitor, rapamycin, caused marked inhibition of 
FBS-stimulated PHAS-I phosphorylation. Collectively, these 
results strongly suggest that PHAS-I phosphorylation in re-
sponse to FBS occurs through a rapamycin-sensitive pathway, 
and that the ERK2 cascade is not involved. 
4. Discussion 
The regulation of PHAS-I by growth factors and insulin 
has been a key issue in recent years. There has been consid-
erable interest in the signalling events leading to insulin-stimu-
lated phosphorylation of PHAS-I, and the importance of 
PHAS-I in regulating the initiation phase of protein synthesis 
[4,5,9,10]. 
Several reports have implicated ERK1/ERK2 as potential 
PHAS-I kinases. PHAS-I was shown to be a very good sub-
strate for ERK2 with a single site, Ser64, being identified as 
the site of phosphorylation in vitro [9]. This was also the 
major site phosphorylated in response to insulin in rat adipo-
cytes [9]. Moreover, phosphorylation of recombinant PHAS-I 
in response to agonist was seen to follow the time course of 
ERK activation [10]. 
To establish the involvement of ERK1/ERK2 in mediating 
events leading to FBS-stimulated PHAS-I phosphorylation in 
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Fig. 2. Rapamycin attenuates FBS-stimulated PHAS-I phosphorylation in 3T3-L1 adipocytes. All cells were incubated in DMEM supplemented 
with 0.25% (w/v) BSA for 72 h. Cells were washed and 32P labelled in phosphate-free buffer (90 min, 37°C). Rapamycin (10 nM) was then 
added (as indicated) and cells were incubated for a further 30 min. In the no rapamycin conditions, diluent controls were performed (0.005% 
DMSO). The final 10 min of labelling was in the presence (+) or absence (-) of FBS (20%). A: Autoradiograph showing phosphorylation of 
PHAS-I; data from densitometric quantitation (arbitrary units) of a representative autoradiograph (where U = upper band and L = lower band 
of PHAS-I) were: lane 1, U = 46218, L = 29343; lane 2, U= 15906, L = 18566; lane 3, U = 61067, L = 3928; lane 4, U = 21583, L= 16506. 
B: Quantitation of PHAS-I phosphorylation seen in A, expressed as a ratio of 32P incorporation into the upper/lower bands. Results are repre-
sentative of two experiments. C: Western blot (using an anti-ERK antibody) indicating the activation state of ERK2 in extracts from the same 
experiment. ERK2* denotes the activated form. Activated ERKl was below the threshold of detection of Western blotting and so is not visible 
in this experiment. D: Quantitation by densitometry of ERK2 activation. ERK2 activation is expressed as a percentage, where the sum of the 
intensity of the ERK2 and ERK2* bands in each condition was taken to be 100%. Results are expressed as means ± half the difference. 
3T3-L1 adipocytes, an antisense phosphorothioate oligonu-
cleotide approach was used. In this cell line ERK2 was the 
major isoform, representing ~ 9 0 % of total cellular ERK 
when measured by Western blotting (see Fig. 1C, lane 1). 
The antisense probe (EAS1) was able to specifically deplete 
~ 9 5 % of ERK2 (Fig. 1C, lanes 3 and 4 and Fig. ID). In 
addition, the ERKl isoform was depleted to undetectable 
levels by EAS1 treatment (Fig. 1C, lanes 3 and 4). The level 
of depletion obtained in this study was in agreement with that 
from previous experiments using EAS1, in which the level of 
depletion was verified by assaying for agonist-stimulated ERK 
activity, using MBP as a substrate [11]. The specificity of 
EAS1 action was determined in this study by the use of a 
scrambled control ODN. Treatment with the scrambled con-
trol ODN had no effect on ERK1/ERK2 expression levels 
(Fig. 1C, lanes 5 and 6 and Fig. ID). Numerous additional 
controls to verify the specificity of the antisense probe have 
been performed, and are described in [11-13]. 
Using this technique, it was possible to determine whether 
ERK1/ERK2 participate in events leading to PHAS-I phos-
phorylation in response to FBS. EAS1 treatment caused sig-
nificant depletion of ERK1/ERK2 (Fig. 1C,D) yet had no 
effect on the level of FBS-stimulated PHAS-I phosphoryla-
tion, when compared with scrambled ODN and no ODN 
control conditions (Fig. 1A, lane 4 compared with lanes 2 
and 6; see also Fig. IB). The lack of correlation between 
the level of ERK1/ERK2 and the amount of PHAS-I phos-
phorylation, implies that ERK1/ERK2 are not responsible for 
mediating PHAS-I phosphorylation in response to FBS. 
With this in mind, an alternative strategy was sought. Di-
rect phosphorylation of PHAS-I by p70S6k is thought unlikely 
[9,23]. However, other components of the p70S6k cascade are 
candidate PHAS-I kinases. To this end, rapamycin was em-
ployed. Rapamycin is a reagent with the ability to selectively 
block mitogen-induced activation of p70S6k and cause the rap-
id inactivation of this kinase in mitogen-stimulated cells [24]. 
It is thought that this inhibition is not exerted directly on 
p70S6k, but on a component involved in controlling its activity 
[24]. 
At a concentration of 10 nM, rapamycin caused marked 
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attenuation of FBS-stimulated PHAS-I phosphorylation nota-
ble by a change in proportion of 32P incorporated into each 
band of PHAS-I (Fig. 2A, lane 4 compared with lane 3). 
When the ratio of 32P incorporation into the upper and lower 
bands was measured, it was apparent that rapamycin had 
inhibited FBS-stimulated PHAS-I phosphorylation such that 
the level was similar to that in control unstimulated cells (see 
Fig. 2B). Moreover, a study of the raw data (see legend to 
Fig. 2) showed that rapamycin treatment prior to FBS stim-
ulation caused an overall decrease in 32P incorporation into 
PHAS-I. In addition, rapamycin had no effect on FBS-stimu-
lated ERK2 activity (Fig. 2C, lane 3 compared with lane 4). 
Taken together, results from this study strongly suggest that 
FBS-stimulated PHAS-I phosphorylation is an ERK1/ERK2-
independent and rapamycin-sensitive event, since it is not af-
fected by a change in ERK1/ERK2 expression levels, but is 
inhibited by rapamycin under conditions where the ERK1/ 
ERK2 activation state remains unaffected. 
These results support those from a previous study that in-
vestigated the kinase cascades involved in insulin-stimulated 
PHAS-I phosphorylation, using PD098059 (a selective MEK 
inhibitor) and rapamycin [23]. Lin and co-workers showed 
that rapamycin inhibits insulin-stimulated PHAS-I phosphor-
ylation in 3T3-L1 adipocytes. Furthermore, PD098059 mark-
edly decreased the effects of insulin on activating ERK1/ 
ERK2, but had no effect on insulin-stimulated PHAS-I phos-
phorylation in this cell line [23]. The use of PD098059 in this 
instance was acceptable since insulin is a weak activator of 
MEK, and consequently insulin-stimulated MEK activation 
can be almost completely inhibited by PD098059 [25]. How-
ever, the use of PD098059 is problematical when using high 
concentrations of agonists that are potent activators of MEK 
(such as FBS, PDGF, EGF and TPA), since a significant 
proportion of agonist-activated MEK remains upon treatment 
with PD098059 (8.9-13.3%). Moreover, an even greater pro-
portion (20-66.3%) of agonist-activated ERK2 remained upon 
PD098059 treatment [25]. Alessi and co-workers [25] also 
noted that PD098059 demonstrates a high level of specificity 
for the MEK isoforms, such that it acts mainly on MEK1 and 
can only weakly inhibit MEK2 activation. The antisense tech-
nique employed in the present study has the advantage of 
being capable of direct and potent inhibition of ERK1 and 
ERK2, regardless of the agonist used to challenge the cells. 
At present, the precise mechanism behind PHAS-I phos-
phorylation still needs some clarification. Growth-factor/insu-
lin stimulation of 3T3-L1 adipocytes appears to stimulate a 
signalling pathway which is rapamycin-sensitive, but it is not 
certain whether the stimulation of this pathway results in in-
hibition of a PHAS-I phosphatase, or stimulation of a PHAS-
I kinase. Similarly, the mechanism of action of rapamycin is 
not fully understood. Although rapamycin is a p70S6k path-
way inhibitor, there is some evidence that it is able to stim-
ulate phosphatase activity in cells. For example, in the case of 
p70S6k, rapamycin causes dephosphorylation of sites which are 
distinct from those phosphorylated in response to mitogens 
[26]. A rapamycin-stimulated PHAS-I phosphatase would 
raise the possibility that PHAS-I phosphorylation was inde-
pendent of p70S6k. Rapamycin sensitivity does therefore not 
necessarily implicate the p70S6k pathway. However, evidence 
in favour of involvement of the p70S6k cascade in mediating 
PHAS-I phosphorylation comes from recent work with wort-
mannin. This agent has been shown to inhibit PI3K activity 
both in vitro and in vivo [27,28], a protein kinase thought to 
be an upstream element of the p70S6k cascade [29]. Wortman-
nin treatment of cells has been shown to inhibit PHAS-I phos-
phorylation, indicating that PI3K activity is required [30]. 
Although much progress has been made in recent years, 
further work is necessary to fully elucidate the signalling 
events and kinases involved in insulin/growth factor-stimu-
lated PHAS-I phosphorylation. 
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